Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab Combinations in Multiple Myeloma
NCT05050097Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of talquetamab in multiple myeloma (MM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Adverse Events by Severity and 2 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05050097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050097.